Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know
Eli Lilly is making a significant move into the vaccine market, although it currently has no vaccines available. The company is focusing on developing vaccines that address unmet medical needs, including a shingles vaccine with fewer side effects than the current standard. Additionally, Lilly aims to potentially introduce the first vaccine for the Epstein-Barr Virus, which is linked to various serious health conditions.
- ▪Lilly has no vaccines on the market but historically helped distribute the original polio vaccine.
- ▪The new vaccines are in earlier-stage development and may take time to reach the market.
- ▪Lilly's shingles vaccine aims to improve tolerability compared to GSK's Shingrix vaccine, with fewer reported side effects.
CNBC — Top files mainly under finance. We currently carry 510 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | CNBC — Top |
| Canonical URL | https://www.cnbc.com/2026/05/27/eli-lilly-makes-a-new-push-into-vaccines-heres-what-to-know.html |
| Publication time | Wed, 27 May 2026 14:57:06 GMT |
| Retrieval time | 2026-05-27T15:03:01.294Z |
| Last seen | 2026-05-27T15:03:01.294Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 2FM05N0fWdO3 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Lilly does not have any vaccines on the market, though it historically helped distribute one of the original polio vaccines. The shots across Lilly's new deals are still in earlier-stage development, so they will likely take time until they reach the market. But what they appear to have in common is that they aim to fill unmet needs, whether that's differentiating from what's already on the market or bringing what could be the first-ever vaccine for certain viruses.For example, Curevo is developing a shot against shingles that Lilly hopes could be as effective as the current standard of care but with fewer side effects.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Top.
Discussion
0 commentsMore from CNBC — Top
